Your browser doesn't support javascript.
loading
Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain.
Della Pietra, Adriana; Krivoshein, Georgii; Ivanov, Konstantin; Giniatullina, Raisa; Jyrkkänen, Henna-Kaisa; Leinonen, Ville; Lehtonen, Marko; van den Maagdenberg, Arn M J M; Savinainen, Juha; Giniatullin, Rashid.
Afiliação
  • Della Pietra A; A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
  • Krivoshein G; A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
  • Ivanov K; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • Giniatullina R; Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
  • Jyrkkänen HK; A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
  • Leinonen V; Department of Neurosurgery, Kuopio University Hospital and Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • Lehtonen M; Department of Neurosurgery, Kuopio University Hospital and Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • van den Maagdenberg AMJM; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
  • Savinainen J; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • Giniatullin R; Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
J Headache Pain ; 24(1): 38, 2023 Apr 11.
Article em En | MEDLINE | ID: mdl-37038131
ABSTRACT

BACKGROUND:

Engaging the endocannabinoid system through inhibition of monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), degrading endocannabinoids (endoCBs) 2-arachidonoylglycerol (2-AG) and anandamide (AEA), was proposed as a promising approach to ameliorate migraine pain. However, the activity of MAGL and FAAH and action of endoCB on spiking activity of meningeal afferents, from which migraine pain originates, has not been explored thus far. Therefore, we here explored the analgesic effects of endoCB enhancement in rat and human meningeal tissues.

METHODS:

Both MAGL and FAAH activity and local 2-AG and AEA levels were measured by activity-based protein profiling (ABPP) and LC-MS/MS, respectively, in rat meninges obtained from hemiskulls of P38-P40 Wistar rats and human meninges from elderly patients undergoing non-migraine related neurosurgery. The action on endoCBs upon administration of novel dual MAGL/FAAH inhibitor AKU-005 on meningeal afferents excitability was tested by investigating paired KCl-induced spiking and validation with local (co-)application of either AEA or 2-AG. Finally, the specific TRPV1 agonist capsaicin and blocker capsazepine were tested.

RESULTS:

The basal level of 2-AG exceeded that of AEA in rat and human meninges. KCl-induced depolarization doubled the level of AEA. AKU-005 slightly increased spontaneous spiking activity whereas the dual MAGL/FAAH inhibitor significantly decreased excitation of nerve fibres induced by KCl. Similar inhibitory effects on meningeal afferents were observed with local applications of 2-AG or AEA. The action of AKU-005 was reversed by CB1 antagonist AM-251, implying CB1 receptor involvement in the anti-nociceptive effect. The inhibitory action of AEA was also reversed by AM-251, but not with the TRPV1 antagonist capsazepine. Data cluster analysis revealed that both AKU-005 and AEA largely increased long-term depression-like meningeal spiking activity upon paired KCl-induced spiking.

CONCLUSIONS:

In the meninges, high anti-nociceptive 2-AG levels can tonically counteract meningeal signalling, whereas AEA can be engaged on demand by local depolarization. AEA-mediated anti-nociceptive effects through CB1 receptors have therapeutic potential. Together with previously detected MAGL activity in trigeminal ganglia, dual MAGL/FAAH inhibitor AKU-005 appears promising as migraine treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Endocanabinoides / Transtornos de Enxaqueca Limite: Aged / Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Endocanabinoides / Transtornos de Enxaqueca Limite: Aged / Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article